Dr. Schwartz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1237 Harding Pl
Ste 3100
Charlotte, NC 28204Phone+1 704-373-0212
Education & Training
- University of ColoradoChief Residency, Internal Medicine, 2012
- Abbott-Northwestern Hospital/Allina Health SystemFellowship, Adult Congenital Heart Disease, 2017 - 2018
- Stanford Health Care-Sponsored Stanford UniversityFellowship, Interventional Cardiology, 2016 - 2017
- Stanford Health Care-Sponsored Stanford UniversityFellowship, Cardiovascular Disease, 2013 - 2016
- University of ColoradoResidency, Internal Medicine, 2010 - 2012
- University of ColoradoInternship, Internal Medicine, 2009 - 2010
- University of Minnesota Medical SchoolClass of 2009
Certifications & Licensure
- CA State Medical License 2013 - Present
- NC State Medical License 2018 - 2025
- SC State Medical License 2020 - 2025
- MN State Medical License 2016 - 2018
- CO State Medical License 2011 - 2015
- American Board of Internal Medicine Cardiovascular Disease
- American Board of Internal Medicine Interventional Cardiology
Publications & Presentations
PubMed
- 1 citationsTranscatheter Edge-to-Edge Repair in Patients With Complex Tricuspid Valve Anatomy.David H Adams, Gilbert H L Tang, Brian K Whisenant, Susheel K Kodali, Gagan D Singh
JACC. Cardiovascular Interventions. 2024-12-09 - 1 citationsAdvanced Imaging Assessment of the Impact of Tricuspid Regurgitation on Cardiac Remodeling: The TRILUMINATE Pivotal Imaging Substudy.João L Cavalcante, Markus Scherer, Miho Fukui, Stamatios Lerakis, Serge Harb
Journal of the American College of Cardiology. 2024-10-30 - 1 citationsLeft atrial to coronary sinus shunting for treatment of heart failure with mildly reduced or preserved ejection fraction: The ALT FLOW Early Feasibility Study 1-year r...Marcus A Urey, Benjamin Hibbert, Ulrich Jorde, Peter Eckman, Trevor Simard
European Journal of Heart Failure. 2024-04-01
Press Mentions
- Evidence of TAVR Benefit Extends to Cardiogenic ShockMay 18th, 2023
- AFib Patients Better off with No Antiplatelet After TAVRMarch 29th, 2020
- Rocket Pharmaceuticals Presents Preclinical Data of RP-A501 for Danon Disease at the American Society of Gene and Cell Therapy 2019 Annual MeetingMay 2nd, 2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: